ArticleThe Lancet regional health. Western Pacific2026
Burden of cardiovascular diseases in the Asia-Pacific region from 1990 to 2023, with forecasts to 2050: a secondary analysis of the Global Burden of disease study 2023.
Article in The Lancet regional health. Western Pacific, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cardiovascular disease (CVD) is the leading cause of death globally, with the Asia-Pacific region home to over two-thirds of the world's population, bearing over half of this burden. This study aims to characterise historical trends and forecast CVD burden in the Asia-Pacific from 1990 to 2050, identifying disparities by geographic subregions, sociodemographic index (SDI), and age-sex strata. Methods: Historical (1990-2023) and forecasted (2025-2050) trends in CVD disability-adjusted life years (DALYs) and mortality across 39 Asia-Pacific countries were examined using Global Burden of Disease Study 2023. Findings: In the Asia-Pacific, CVD accounted for 241.2 million DALYs (55.3% of global) in 2023. Crude DALYs rose by 51.3% from 1990 to 2023, despite 36.2% reduction in age-standardised DALYs. Crude DALYs will rise further by 10.7% from 2025 to 2050. Atherosclerotic CVD is the key driver of morbidity, with stroke (1255.0 DALYs per 100,000 population) projected to plausibly surpass ischaemic heart disease (1148.7 DALYs per 100,000 population) by 2050. Disparities in CVD burden exist across SDI (low and low-middle SDI bearing the highest burden), geography (Oceania bearing the highest burden), and age-sex categories (DALYs peaking earlier in males by at least 5 years). Interpretation: The net effect of gains in CVD prevention is offset by the rising crude CVD burden owing to the growing and ageing population. The heterogeneity in CVD burden across countries of different socioeconomic development poses unique challenges in tackling CVD in the Asia-Pacific. Funding: SingHealth Duke-National University of Singapore Cardiovascular Sciences Academic Clinical Programme, the National Medical Research Council of Singapore, and the Stafford Fox Foundation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.